KLK3 and cancer: The results showed that subjects with higher baseline PSA levels were more likely to experience PSA progression (Fig 3B), which may seem counterintuitive given that higher baseline PSA was associated with higher drug-killing effect on leuprorelin-sensitive PSA-producing cancer cells in our model.